Roquefort Therapeutics' chairman Stephen West talks to Proactive London's Katie Pilbeam about filing for a patent for a new class of midkine-targeting drugs.
Midkine is a heparin-binding growth factor, which, when over-expressed, is linked with a whole host of nasty ailments including cancer, inflammation and autoimmune diseases
He says this could be 'incredible lucrative' for the company following what it termed 'very positive pre-clinical trials'.